Menu Search
Equities

Rxsight Inc

RXST:NMQ

Rxsight Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)45.29
  • Today's Change0.24 / 0.53%
  • Shares traded168.58k
  • 1 Year change+58.75%
  • Beta1.1213
Data delayed at least 15 minutes, as of Nov 22 2024 19:17 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy5
Outperform4
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 9 analysts offering 12 month price targets for Rxsight Inc have a median target of 65.00, with a high estimate of 70.00 and a low estimate of 56.00. The median estimate represents a 44.28% increase from the last price of 45.05.
High55.4%70.00
Med44.3%65.00
Low24.3%56.00

Earnings history & estimates in USD

On Nov 07, 2024, Rxsight Inc reported 3rd quarter 2024 losses of -0.16 per share. This result exceeded the -0.25 consensus loss of the 8 analysts covering the company and exceeded last year's 3rd quarter results by 54.29%.
The next earnings announcement is expected on Mar 04, 2025.
Average growth rate+16.39%
Rxsight Inc reported annual 2023 losses of -1.41 per share on Feb 28, 2024.
Average growth rate+36.99%
More ▼

Revenue history & estimates in USD

Rxsight Inc had 3rd quarter 2024 revenues of 35.31m. This bettered the 35.06m consensus of the 8 analysts covering the company. This was 101.92% above the prior year's 3rd quarter results.
Average growth rate+12.86%
Rxsight Inc had revenues for the full year 2023 of 89.08m. This was 81.77% above the prior year's results.
Average growth rate+99.34%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.